Introduction

Endoscopic transpapillary gallbladder drainage (ETGBD) has been reported to be effective for acute cholecystitis, for which emergency cholecystectomy and percutaneous transhepatic gallbladder drainage (PTGBD) are considered to be high risk because of coagulopathy, administration of antithrombotic drugs, and poor physical condition [1–5]. In previous reports, two types of ETGBD – endoscopic naso-gallbladder drainage (ENGBD) and endoscopic gallbladder stenting (EGBS) – showed no difference in technical success, clinical success, or early adverse events (AEs) [6–9]. Although both types are suitable for treatment of acute cholecystitis, EGBS is considered to be superior in terms of patient quality of life [6].

In general, traditional biliary plastic stents are substituted for gallbladder stents in EGBS. However, there is no sufficient evidence about which type of plastic stent is suitable, especially for long-term placement. Although standard biliary plastic stents are generally substituted for gallbladder stents in endoscopic transpapillary gallbladder stenting (EGBS), there is no sufficient evidence about what type of plastic stent is suitable. We examined outcomes of EGBS using standard biliary stents and a novel stent for acute cholecystitis and evaluated the efficacy of the novel stent.

ABSTRACT

Background and study aims: Biliary plastic stents are generally substituted for gallbladder stents in endoscopic transpapillary gallbladder stenting (EGBS), there is no sufficient evidence about what type of plastic stent is suitable. We examined outcomes of EGBS using standard biliary stents and a novel stent for acute cholecystitis and evaluated the efficacy of the novel stent.

Patients and methods: Seventy patients with acute cholecystitis in whom EGBS was performed were evaluated retrospectively. We performed EGBS in 23 patients using the novel stent (novel stent group) and 47 patients using standard biliary stents (pigtail: 35, straight: 12) (control group). In the two groups, we examined outcomes of EGBS.

Results: There were no significant differences in patient backgrounds or rates of technical success, clinical success, or early adverse events (AE) between the novel stent group and the control groups. However, rates of late AEs were 4.3% in the novel stent group (liver abscess: 1) and 40.4% in the control group (stent migration: 15, recurrence of cholecystitis: 4), indicating a significantly higher rate in the control group (P=0.004). The rate of stent migration was significantly higher in the control group (P=0.006). Multivariate analysis identified a straight type stent as the risk factor for stent migration (odds ratio: 8.81, 95% confidence interval: 1.66–46.83).

Conclusions: The novel stent had significantly lower rates of late AEs and stent migration. Thus, for long-term stent placement, the novel stent was more effective than traditional biliary stents.
plastic stents have a straight shaft, gallbladder stents are placed with a deeper curve than biliary stents because of anatomical features. Thus, problems may be encountered, such as stent migration due to strong axial force and kinking at the bent portion. Moreover, because a longer stent is often needed for the gallbladder than for the bile duct, a traditional biliary stent may be too short for EGBS.

To overcome these problems, we developed a new design for a plastic stent for EGBS. In this study, we examined short- and long-term outcomes of EGBS using standard stents and the novel stent for acute cholecystitis and evaluated the efficacy of the novel stent.

Patients and methods

Patients

A total of 198 patients underwent ETGBD (117 males and 81 females; age, 73.6 ± 11.7 years) (mean ± standard deviation [SD]) for acute cholecystitis at St. Marianna University School of Medicine Hospital between March 2011 and September 2017. None of the patients were suitable candidates for emergency cholecystectomy and percutaneous transhepatic gallbladder drainage (PTGBD) because of high risk of coagulopathy, administration of antithrombotic drugs, poor physical condition, advanced age, or coexistence of choleclocholithiasis. In terms of anatomy, 190 patients had normal stomachs, four had Billroth-I reconstruction, three had Billroth-II reconstruction, and one had Roux-en-Y (R-Y) reconstruction. Although bile duct cannulation was unsuccessful in one patient and guidewire (GW) insertion into the gallbladder was unsuccessful in 20 patients, the GW could be placed into the gallbladder in 177 patients. In our hospital, after placing the GW into the gallbladder, a 7-Fr tapered catheter with side holes is inserted into the gallbladder to suction bile and irrigate it with saline. In two patients, insertion of the tapered catheter was impossible. Among the 175 patients in whom the tapered catheter could be inserted, 80 underwent ENGBD, 82 underwent EGBS, and 13 underwent endoscopic gallbladder aspiration.

Among the 82 patients who underwent EGBS, 12 patients in whom we used modified stent created by cutting various types of nasobiliary tube were excluded. In total, 70 patients in whom EGBS was performed using the newly designed stent or standard biliary stents (39 males and 31 females; age, 75.0 ± 11.5 years) were selected as subjects and were evaluated retrospectively. After September 2016, we performed EGBS in 23 patients using the newly designed stent and classified these patients into the novel stent group. On the other hand, we defined 47 patients who underwent EGBS using standard biliary stents (double-pigtail type, 35; straight type, 12) before August 2016 prior to introduction of the newly designed stent as the control group (Fig. 1).

EGBS technique

We used a duodenoscope (JF260V or TJF260V; Olympus Medical Systems, Tokyo, Japan) and performed bile duct cannulation by conventional contrast cannulation or wire-guided cannulation. After bile duct cannulation, a hydrophilic GW (e.g., Radifocus, Terumo Co., Ltd., Tokyo, Japan) was passed through the cystic duct and inserted into the gallbladder. After changing the GW to a stiff type, we inserted a 7-Fr tapered catheter with side holes (CX-PTCD kit [PD-EN7F (ST) 180C4], Gadelius Medical, Tokyo, Japan) into the gallbladder over the GW, suctioned the bile, and subsequently irrigated the gallbladder with saline (Fig. 2). Next, we measured the length from the papilla to the gallbladder using the GW and placed the stent so that the tip was at the fundus of the gallbladder.

All endoscopic retrograde cholangiopancreatography (ERCP) procedures were performed under the supervision of an expert who has performed more than 1000 such procedures. Gabexate mesylate was administered at a dosage of 600 mg/day on the day of the procedure to all patients to prevent post-ERCP pancreatitis.

Novel stent

We developed a novel stent for EGBS (GBest-N stent; Hanaco Medical Co., Saitama, Japan) (Fig. 3). The length of the novel stent has a variation of 11 cm, 13 cm, 15 cm, 17 cm, and 19 cm. The tip of the stent has a three-dimensional spiral-shaped structure, and there are side holes inside the spiral. The spiral-shaped tip is expected to prevent migration of the stent. Further, by opening the side holes inside of the spiral part of the stent, it is anticipated that the side holes will not be obstructed even if the stent adheres to the contracted gallbladder wall and drainage will be maintained. The shaft of the stent is 7 Fr and
semicircular and it also has side holes. When inserted into the gallbladder, the stent is often placed in a curved manner because of the anatomical structure. Because the stent is semicircular, it fits well and is not expected to migrate because the axial force of the stent is reduced. In patients with abnormal coagulation, endoscopic sphincterotomy (EST) cannot be performed, and cholestasis could develop at the papilla. The side holes on the shaft are designed to drain the bile from the common bile duct. The distal side of the stent is straight, with a flap to prevent proximal migration. ▶ Fig. 4 shows placement of a novel stent into the gallbladder.

**Stents used in the control group**

The stents used in the control group were as follows: double-pigtail stents: 35 [AdvaniX (Boston Scientific, Natick, Massachusetts, United States): 16, SET-ERBD-72 stents (Hanaco Medical Co., Saitama, Japan): 12, CX-T stents (Gadelius Medical, Tokyo, Japan): 5, PBD-203 stent (Olympus Medical Systems, Tokyo, Japan): 1, and Zimmon biliary stent (Cook Japan, Tokyo, Japan): 1]; straight type stents: 12 [Through Pass (Gadelius Medical, Tokyo, Japan): 11 and CX-T stent (Gadelius Medical, Tokyo, Japan): 1].

**Measurements**

In the novel stent group and the control group, we retrospectively examined and compared the following: patient background, details of endoscopic procedures, technical success rate of EGBS, clinical success rate for acute cholecystitis, early AEs, and late AEs. Cholecystitis severity was determined according to the Tokyo Guidelines 2013 (TG13) for acute cholecystitis [10]. We defined technical success of EGBS as the tip of the stent remaining in the gallbladder and clinical success as
when clinical symptoms and laboratory test results showed an improving tendency within 3 days after EGBS. Early AEs were those that occurred within 7 days, and late AEs were those that occurred at least 8 days after EGBS. The diagnosis and severity of AEs included pancreatitis, bleeding, perforation, and cholangitis based on the consensus guidelines by Cotton et al. [11]. We defined as stent distal migration not only when the stent migrated to the intestine or out of the body but also when a large part of the stent tip slipped out of the gallbladder. Especially with a pigtail stent, migration was defined as when only the tip of the stent was caught in the neck of gallbladder or cystic duct (▶Fig. 5).

This study was approved by the Institutional Review Board of St. Marianna University School of Medicine (approval number: 3891).

Statistical analysis

We used StatMate IV (ATMS Co., Ltd., Tokyo, Japan) for statistical analysis to compare the two groups and performed the chi-square test, Fisher’s exact test, and Welch’s t test as needed. Univariate and multivariate logistic regression analyses were performed using SPSS (version 19; SPSS, Chicago, IL, USA). A P value < 0.05 was considered to be statistically significant.
Results

Patient backgrounds

There was no significant difference between the novel stent group and the control groups in terms of age, sex, severity of cholecystitis, comorbidities (cholecystolithiasis, choledocholithiasis, malignant diseases), history of procedure for papilla of Vater, parapapillary diverticulum, or use of antithrombotic drugs (not significant; N.S.) (▶ Table 1).

Details of endoscopic procedures

▶ Table 2 show details of the endoscopic procedures. Patients in whom EST was performed before EGBS comprised 34.8 % (8/23) of the novel stent group and 40.4 % (19/47) of the control group, showing no difference (N.S.). Stent diameter and length used for EGBS were no different between the two groups (N.S.). Although there was no significant difference, the rate of endoscopic biliary drainage was slightly lower in the novel stent group [8.7 % (2/23) vs 23.4 % (11/47), \( P = 0.246 \)]. All endoscopic pancreatic stenting was performed to prevent post-ERCP pancreatitis.

Technical and clinical success rates for EGBS

In 70 patients in whom the GW and the tapered catheter could be inserted into the gallbladder before EGBS, the technical success rate for EGBS was 100 % in both the novel stent and control groups.

The clinical success rate for acute cholecystitis was 100 % (23/23) in the novel stent group and 95.7 % (45/47) in the control group, indicating no significant difference (N.S.) (▶ Table 3). The stents used in two patients in whom clinical improvement could not be obtained in the control group were both double-pigtail type 7 Fr-15 cm long Advanix (Boston Scientific). In one patient, poor drainage due to a kink in the stent was improved by exchanging the stent with a double-pigtail 7 Fr-16 cm long SET-ERBD-72 stent (Hanaco Medical Co.). In the other patient, cholestasis at the papilla was due to stent placement without EST, and cholecystitis was improved by performing additional EST and endoscopic biliary stenting (EBS).

Adverse events

The details of AEs are shown in ▶ Table 3. The rate of early AEs was 13.0 % (3/23) in the novel stent group and 17.0 % (8/47) in the control group, indicating no significant difference (N.S.). In the novel stent group, early AEs included mild pancreatitis in one patient, EST bleeding in one, and obstructive jaundice in one. On the other hand, in the control group, there was mild

<table>
<thead>
<tr>
<th>▶ Table 1 Patient characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>No. of patients</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
</tr>
<tr>
<td>Sex (male/female)</td>
</tr>
<tr>
<td>Severity of cholecystitis</td>
</tr>
<tr>
<td>Severe</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Cholecystolithiasis</td>
</tr>
<tr>
<td>Choledocholithiasis</td>
</tr>
<tr>
<td>Malignant diseases</td>
</tr>
<tr>
<td>Malignant biliary stricture</td>
</tr>
<tr>
<td>Previous procedures for papilla</td>
</tr>
<tr>
<td>EST</td>
</tr>
<tr>
<td>EPBD</td>
</tr>
<tr>
<td>Pre-cut</td>
</tr>
<tr>
<td>Pre-cut + EPBD</td>
</tr>
<tr>
<td>Papillary diverticulum</td>
</tr>
<tr>
<td>Use of antithrombotic drug</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>SD, standard deviation; EST, endoscopic sphincterotomy; EPBD, endoscopic papillary balloon dilation</td>
</tr>
</tbody>
</table>
pancreatitis in two patients, EST bleeding in one, obstructive jaundice in three, cystic duct perforation in one, and a stent kink in one. Among the two groups, obstructive jaundice in four patients was caused by cholestasis at the papilla because of stent placement without EST, and additional EBS and/or EST led to improvement. All early AEs were improved by conservative therapy or endoscopic procedures.

Table 2 Endoscopic procedures.

<table>
<thead>
<tr>
<th></th>
<th>Novel stent group</th>
<th>Control group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>23</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Endoscopic procedure for papilla</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ EST</td>
<td>8</td>
<td>19</td>
<td>0.649</td>
</tr>
<tr>
<td>▪ No</td>
<td>15</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Endoscopic gallbladder stenting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ Novel stent</td>
<td>23</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>▪ Pigtail type</td>
<td>0</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>▪ Straight type</td>
<td>0</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>▪ Caliber of stent (7Fr/5Fr)</td>
<td>23/0</td>
<td>46/1</td>
<td>0.713</td>
</tr>
<tr>
<td>Length of stent (≤ 15 cm/≥ 16 cm)</td>
<td>18/5</td>
<td>33/14</td>
<td>0.477</td>
</tr>
<tr>
<td>Common bile duct stone removal</td>
<td>5</td>
<td>9</td>
<td>0.949</td>
</tr>
<tr>
<td>Biliary drainage</td>
<td>2</td>
<td>11</td>
<td>0.246</td>
</tr>
<tr>
<td>ENBD</td>
<td>1</td>
<td>3</td>
<td>0.839</td>
</tr>
<tr>
<td>EBS</td>
<td>1</td>
<td>8</td>
<td>0.268</td>
</tr>
<tr>
<td>Pancreatic stenting</td>
<td>4</td>
<td>11</td>
<td>0.790</td>
</tr>
</tbody>
</table>

EST, endoscopic sphincterotomy; ENBD, endoscopic nasobiliary drainage; EBS, endoscopic biliary stenting

Table 3 Clinical outcomes and adverse events.

<table>
<thead>
<tr>
<th></th>
<th>Novel stent group</th>
<th>Control group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>23</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Clinical success (% (n))</td>
<td>100 (23)</td>
<td>95.7 (45)</td>
<td>0.810</td>
</tr>
<tr>
<td>Adverse events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▪ Early (≤ 7 days) (% (n))</td>
<td>13.0 (3)</td>
<td>17.0 (8)</td>
<td>0.936</td>
</tr>
<tr>
<td>▪ Pancreatitis (n)</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>▪ EST bleeding (n)</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>▪ Obstructive jaundice (n)</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>▪ Cystic duct perforation (n)</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>▪ Kink of stent (n)</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>▪ Delay (&gt; 7 days) (% (n))</td>
<td>4.3 (1)</td>
<td>40.4 (19)</td>
<td>0.004</td>
</tr>
<tr>
<td>▪ Stent distal migration (n)</td>
<td>0</td>
<td>15</td>
<td>0.006</td>
</tr>
<tr>
<td>▪ Cholecystitis (n)</td>
<td>0</td>
<td>4</td>
<td>0.372</td>
</tr>
<tr>
<td>▪ Liver abscess (n)</td>
<td>1</td>
<td>0</td>
<td>0.713</td>
</tr>
<tr>
<td>▪ Total (% (n))</td>
<td>17.4 (4)</td>
<td>57.4 (27)</td>
<td>0.004</td>
</tr>
<tr>
<td>Follow-up period (mean ± SD (range) days)</td>
<td>120 ± 143 (4 – 573)</td>
<td>162 ± 252 (4 – 950)</td>
<td>0.371</td>
</tr>
</tbody>
</table>

EST, endoscopic sphincterotomy; SD, standard deviation
Early AEs during the observation period [novel stent group, 120 ± 143 days; control group, 162 ± 252 days (mean ± SD); P=0.371] were 4.3 % (1/23) in the novel stent group and 40.4 % (19/47) in the control group, indicating a significantly higher rate in the control group (P=0.004). Details of late AEs were liver abscess in one patient in the novel stent group and stent distal migration in 15 and recurrence of cholecystitis in four in the control group. The rate of stent distal migration in the control group was high (31.9 % (15/47)), which was significantly higher than that in the novel stent group (P=0.006). In addition, stent migration was the cause of recurrence of cholecystitis in four patients in the control group.

The total rate of combined early and late AEs was 17.4 % (4/23) in the novel stent group and 57.4 % (27/47) in the control group, indicating a significantly higher rate in the control group (P=0.004).

A comparison of AEs for each type of stents is shown in Table 4. Although there was no difference in early AEs among novel, pigtail, and straight stents, the novel stent had significantly lower rates of late AEs and stent distal migration compared with the other stents. Among the three stent types, the straight stent had the highest rates of late AEs and stent distal migration. Mean duration from stent placement to migration in the control group was 69.5 ± 69.0 days (mean ± SD). There was no difference in time from stent placement to migration between pigtail and straight stents (N.S.).

Risk factors for stent distal migration

Univariate and multivariate logistic regression analyses were performed to identify risk factors for stent distal migration. Univariate analysis identified straight type stent as the only significant risk factor for stent distal migration (P=0.016; odds ratio (OR), 5.44; 95 % confidence interval (CI), 1.43–20.72). Moreover, the newly designed stent significantly correlated with a lack of migration (P=0.001; OR, 0.58; 95 % CI, 0.47–0.73) (Table 5). Multivariate analysis also identified straight type stent as significant risk factor for stent distal migration (P=0.011; OR, 8.81; 95 % CI, 1.66–46.83) (Table 6).

Discussion

Although ETGBD with ENGBD or EGBS is an effective alternative method when emergency cholecystectomy and PTGBD are considered high risk [1–5], ETGBD is technically difficult. In the last 10 years, the technical success rate is reported to be 64 % to 96 % [5–9,12–20]. ETGBD’s technical difficulty is associated with the inherent complexity of inserting the GW into the gallbladder. Moreover, even when GW placement in the gallbladder is successful, subsequent placement of the stent may be complicated. In this study, if a 7-Fr tapered catheter could be inserted into the gallbladder before stent insertion, the technical success rate was 100 % for both novel stent and control groups. With this approach of insertion of a tapered catheter into the gallbladder before stent placement, cystic duct bougie can be achieved and subsequent insertion of any stent is expected to improve. In addition, we consider successful insertion of a tapered catheter as predictive of subsequent success of stent placement. Theoretically, the longer, tortuous tip of the novel stent might be an obstacle to pushing the stent and it may be inferred that it is harder to insert than standard stents. However, using the novel stent, it was not hard to insert into the gallbladder compared with standard stents. The tapered tip and relatively hard shaft of the novel stent may contribute to good insertability. We acknowledge that the stent may have been easy to place in the cases in this study because no cases were included in which the 7 Fr tapered catheter could not be inserted into the gallbladder.

Clinical success rates with ETGBD for acute cholecystitis are reported to be 83 % to 100 % in per-protocol analyses [5–9,12–21]. It has also been reported that the clinical success rate with ETGBD is roughly 10 % lower than the technical success rates in intention-to-treat analysis because of the accumulation of...
purulent material, sludge, or gallstones, thus hindering effective drainage [13, 22, 23]. In this study, clinical success rates for cases in which EGBS was technically successful were 100% in the novel stent group and 95.7% in the control group, which are both extremely favorable. Suctioning viscous bile and irrigation of the gallbladder with saline through a tapered catheter prior to stent placement may have contributed to this favorable outcome.

EGBS-specific early AEIs include cystic duct perforation, stent kinking, and obstructive jaundice without EST. In subjects undergoing EGBS, EST often cannot be performed because of abnormal coagulation; however, stent placement without EST could lead to outflow obstruction of bile at the papilla. Therefore, with the novel stent, side holes were opened at the shaft in anticipation of bile drainage from the common bile duct. However, there was one case of obstructive jaundice due to cholestasis in the novel stent group and the efficacy of the side hole at the shaft was unclear.

In this study, the rate of late AEIs in the control group was high (40.4%), and the rate of stent distal migration was quite high at 31.9%. Moreover, in four patients who developed acute cholecystitis in the control group, the cause was stent distal migration. According to previous reports, stent distal migration not only causes exacerbation or recurrence of cholecystitis but also leads to severe complications such as pancreatitis [24] and intestinal perforation [25, 26]. Therefore, especially in cases of long-term stent placement, stent selection should be performed with prevention of migration in mind. In this study, univariate analysis indicated that a straight stent was the risk factor associated with migration; thus, straight stents should be avoided for long-term placement of EGBS. Inoue et al. [19] reported good long-term outcomes using a newly designed stent that was straight stent on the distal side and a small half-pigtail one on the proximal side (stent migration: 0% [0/23], cholecystitis recurrence: 0% [0/23], cholangitis: 4.3% [1/23]). Thus, we assumed that a straight stent might be associated with less migration than a double-pigtail type, and we used straight stents for a while. However, results from this study show that stents that are straight on both proximal and distal sides often migrate.

### Table 5: Risk factors for stent distal migration (univariate analysis).

<table>
<thead>
<tr>
<th></th>
<th>Migration (+)</th>
<th>Migration (−)</th>
<th>P value</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>15</td>
<td>55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (&gt;80)</td>
<td>4</td>
<td>24</td>
<td>0.373</td>
<td>0.470 (0.133–1.660)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>7</td>
<td>24</td>
<td>1.000</td>
<td>1.130 (0.359–3.555)</td>
</tr>
<tr>
<td>Novel stent</td>
<td>0</td>
<td>23</td>
<td>0.001</td>
<td>0.582 (0.465–0.728)</td>
</tr>
<tr>
<td>Pigtail stent</td>
<td>9</td>
<td>26</td>
<td>0.561</td>
<td>1.637 (0.524–5.341)</td>
</tr>
<tr>
<td>Straight stent</td>
<td>6</td>
<td>6</td>
<td>0.016</td>
<td>5.444 (1.431–20.716)</td>
</tr>
<tr>
<td>Length of stent (&lt;12 cm)</td>
<td>4</td>
<td>5</td>
<td>0.091</td>
<td>3.636 (0.838–15.782)</td>
</tr>
<tr>
<td>Severe cholecystitis</td>
<td>2</td>
<td>5</td>
<td>0.637</td>
<td>1.538 (0.267–8.850)</td>
</tr>
<tr>
<td>Acalculus cholecystitis</td>
<td>2</td>
<td>7</td>
<td>1.000</td>
<td>1.055 (0.195–5.699)</td>
</tr>
<tr>
<td>Malignant biliary stricture</td>
<td>0</td>
<td>4</td>
<td>0.571</td>
<td>0.927 (0.861–0.999)</td>
</tr>
<tr>
<td>Post-EST papilla</td>
<td>8</td>
<td>29</td>
<td>1.000</td>
<td>1.025 (0.326–3.217)</td>
</tr>
<tr>
<td>Biliary drainage</td>
<td>2</td>
<td>11</td>
<td>0.720</td>
<td>0.615 (0.121–3.137)</td>
</tr>
<tr>
<td>Pancreatic stenting</td>
<td>4</td>
<td>11</td>
<td>0.723</td>
<td>1.455 (0.388–5.453)</td>
</tr>
<tr>
<td>Papillary diverticulum</td>
<td>5</td>
<td>28</td>
<td>0.258</td>
<td>0.482 (0.146–1.595)</td>
</tr>
</tbody>
</table>

OR, odds ratio; CI, confidence interval; EST, endoscopic sphincterotomy

### Table 6: Risk factors for stent distal migration (multivariate analysis).

<table>
<thead>
<tr>
<th></th>
<th>P value</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (&gt;80)</td>
<td>0.177</td>
<td>0.343 (0.073–1.621)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>0.726</td>
<td>1.297 (0.303–5.556)</td>
</tr>
<tr>
<td>Stent type (straight)</td>
<td>0.011</td>
<td>8.805 (1.656–46.826)</td>
</tr>
<tr>
<td>Length of stent (&lt;12 cm)</td>
<td>0.107</td>
<td>4.738 (0.715–31.406)</td>
</tr>
<tr>
<td>Severe cholecystitis</td>
<td>0.537</td>
<td>1.862 (0.259–13.367)</td>
</tr>
<tr>
<td>Acalculus cholecystitis</td>
<td>0.987</td>
<td>1.019 (0.106–9.806)</td>
</tr>
<tr>
<td>Post-EST papilla</td>
<td>0.770</td>
<td>1.247 (0.284–5.476)</td>
</tr>
<tr>
<td>Biliary drainage</td>
<td>0.419</td>
<td>0.450 (0.065–3.123)</td>
</tr>
<tr>
<td>Pancreatic stenting</td>
<td>0.230</td>
<td>3.213 (0.478–21.622)</td>
</tr>
<tr>
<td>Papillary diverticulum</td>
<td>0.313</td>
<td>0.459 (0.101–2.084)</td>
</tr>
</tbody>
</table>

OR, odds ratio; CI, confidence interval; EST, endoscopic sphincterotomy
In addition, the high rate of stent migration compared with previous reports may be related to the definition of stent migration. We defined stent distal migration not only as when a stent migrated to the intestine or out of the body but also when the tip of the stent was caught in the neck of gallbladder or cystic duct (Fig. 5). In previous reports, there are no detailed descriptions of the definition of stent migration, but when the tip of the stent was caught in the neck of gallbladder or cystic duct, it may not have been judged as a migration.

Remarkably, there was no stent distal migration in the novel stent group. We assume that the factors that contributed to prevention of stent migration include: (1) the three-dimensional spiral shape of the stent tip; (2) the maximum stent length of 19 cm, allowing for placement at a sufficient depth; (3) the semicircular shape of the stent shaft reducing the stent’s axial force; and (4) the straight distal end of the stent, meaning that it is less affected by food passing and intestinal peristalsis. We believe that among these factors, the semicircular shape of the stent shaft was the most effective in preventing stent migration. Standard biliary stents have a straight shaft, which requires bending when placed in the gallbladder to accommodate the regional anatomy. Therefore, a straight shaft must create a strong axial force [27, 28]. We consider that the semicircular shape of the stent with low axial force contributes to prevention of migration. Although the basic policy in this study was to place the stent tip at the fundus of the gallbladder in both the novel stent group and the control group, there may be more cases in which the stent can be inserted to the target site because of the longer lengths available. Moreover, multivariate analysis in this study revealed that the straight stent was a risk factor for migration. Although the distal end of the novel stent is straight, there were no cases of migration in the novel stent group. It is apparent that when only the distal end is straight, it is not a risk factor for migration.

Several limitations of this study exist. First, the design is single-center and retrospective. In addition, although there were no statistical differences and the novel stent group had a slightly shorter observation period compared with the control group [120 ± 143 vs 162 ± 252 (mean, days)]. However, because the observation period of the novel stent group was longer than the mean duration from placement to migration in the control group [69.5 ± 69.0 (mean, days)], we believe that evaluation was sufficient. To resolve these limitations, comparison and verification of the novel stent and traditional stents with a randomized controlled trial are desirable in the future.

Conclusion

In conclusion, EGBS using the novel stent (GBest-N stent) led to good results for technical and clinical success, and AEs. In terms of technical and clinical success and early AEs, EGBS was effective for acute cholecystitis regardless of whether the traditional or novel stent was used. However, in terms of long-term outcomes, stent distal migration and associated recurrence of cholecystitis occur frequently with the traditional biliary stent. The novel stent had significantly lower rates of late AEs and stent distal migration compared with the traditional biliary stent. Thus, if long-term stent placement is necessary, the novel stent is more effective.

Competing interests

None

References


